When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CBAY - CymaBay doubles as panel sees no liver injury in NASH drug study
CymaBay Therapeutics Inc.
CymaBay Therapeutics (NASDAQ:CBAY) +111.9% after-hours following the company's smaller than forecast Q1 loss and news that an "independent expert panel" unanimously agreed that there is no clinical, biochemical or histological evidence of liver injury induced by its seladelpar liver disease drug in the company's Phase 2b NASH trial.
More news on: CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the move,